MedTrace Logo

A Prospective Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure

NCT02998840 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2022-09-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate and compare the efficacy of B244 in treating patients with hypertension.

Conditions

  • Prehypertension
  • Hypertension, Stage I

Interventions

BIOLOGICAL

B244

odorless suspension

BIOLOGICAL

Vehicle

odorless suspension

Sponsors & Collaborators

  • Veristat, Inc.

    collaborator OTHER

  • AOBiome LLC

    lead INDUSTRY

Principal Investigators

  • Larry Weiss, MD · Chief Medical Officer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2017-04-25
Completion
2017-06-26

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02998840 on ClinicalTrials.gov